ArticleBlood2005
Therapeutic potential of a tumor-specific, MHC-unrestricted T-cell receptor expressed on effector cells of the innate and the adaptive immune system through bone marrow transduction and immune reconstitution.
Article in Blood, 2005. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 43 citations in OpenAlex.
- Cytotoxic T-lymphocyte immunotherapy for ovarian cancer: a pilot study.Journal of immunotherapy (Hagerstown, Md. : 1997)Trial
- Selection, engineering, and in vivo testing of a human leukocyte antigen-independent T-cell receptor recognizing human mesothelin.PloS one · 2024Article
- Transcription-Related Dynamics from Immune Disability into Endogenous Innovation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2019Article
- In Vitro Differentiation of T Cells from Murine Pluripotent Stem Cells.Methods in molecular biology (Clifton, N.J.) · 2019Article
- Cancer vaccines: translation from mice to human clinical trials.Current opinion in immunology · 2018Review
- Antibodies elicited by the first non-viral prophylactic cancer vaccine show tumor-specificity and immunotherapeutic potential.Scientific reports · 2016Article
- A role for multiple chimeric antigen receptor-expressing leukocytes in antigen-specific responses to cancer.Oncotarget · 2016Article
- Structural interplay between germline interactions and adaptive recognition determines the bandwidth of TCR-peptide-MHC cross-reactivity.Nature immunology · 2016Article
- Costimulation with anti-cluster of differentiation 3 and anti-cluster of differentiation 28 reduces the activity of mucin 1-stimulated human mononuclear cells.Oncology letters · 2016Article
- TGFα-PE38 enhances cytotoxic T-lymphocyte killing of breast cancer cells.Oncology letters · 2014Article
- Hematopoietic stem cells for cancer immunotherapy.Immunological reviews · 2014Review
- Dendritic cells enhance the activity of human MUC1-stimulated mononuclear cells against breast cancer.Oncoimmunology · 2013Article
- Directed differentiation of induced pluripotent stem cells towards T lymphocytes.Journal of visualized experiments : JoVE · 2012Article
- How (specific) would like your T-cells today? Generating T-cell therapeutic function through TCR-gene transfer.Frontiers in immunology · 2012Article
- Generation of a tumor vaccine candidate based on conjugation of a MUC1 peptide to polyionic papillomavirus virus-like particles.Cancer immunology, immunotherapy : CII · 2010Article
- Cytokine-induced NK-like T cells: from bench to bedside.Journal of biomedicine & biotechnology · 2010Review
- Lentiviral vectors encoding human MUC1-specific, MHC-unrestricted single-chain TCR and a fusion suicide gene: potential for universal and safe cancer immunotherapy.Cancer immunology, immunotherapy : CII · 2009Article
- Article
- Extrathymic generation of tumor-specific T cells from genetically engineered human hematopoietic stem cells via Notch signaling.Cancer research · 2007Article
- Cloning and expression of human membrane-bound and soluble engineered T cell receptors for immunotherapy.Journal of biomedicine & biotechnology · 2006Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
Abstract
T-cell receptor (TCR) with unique major histocompatibility complex (MHC)-unrestricted antigen-binding properties was isolated from a human T-cell clone specific for the tumor antigen MUC1. This TCR binds its epitope on the MUC1 protein without the requirement of processing and presentation. A single-chain Valpha/Vbeta/Cbeta (scTCR) was fused to a CD3 zeta (zeta) chain to allow expression on the surface of cells of the innate (granulocytes, macrophages, natural killer [NK] cells) as well as the adaptive (T and B cells) immune system. To test the ability of the cells of the innate immune system to reject a tumor when provided with a tumor antigen-specific TCR, we reconstituted severe combined immunodeficiency (SCID) mice with bone marrow cells transduced with a retroviral vector encoding this receptor and challenged them with a MUC1-positive human tumor. These mice controlled the growth of the tumor significantly better than the control mice. We performed a similar experiment in immunocompetent mice transgenic for human MUC1. Expression of the TCR on large percentages of cells did not result in infiltration or destruction of tissues expressing MUC1. Reconstituted mice controlled the outgrowth of a MUC1-transfected but not the parental control tumor. scTCR expression appears lifelong, suggesting a successful transduction of the self-renewing stem cells.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.